{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:50:53Z","timestamp":1772470253258,"version":"3.50.1"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Health Research Foundation","award":["1U54HD090215-01"],"award-info":[{"award-number":["1U54HD090215-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background: Large-scale screening of drug sensitivity on cancer cell models can mimic in vivo cellular behavior providing wider scope for biological research on cancer. Since the therapeutic effect of a single drug or drug combination depends on the individual patient\u2019s genome characteristics and cancer cells integration reaction, the identification of an effective agent in an in vitro model by using large number of cancer cell models is a promising approach for the development of targeted treatments. Precision cancer medicine is to select the most appropriate treatment or treatments for an individual patient. However, it still lacks the tools to bridge the gap between conventional in vitro cancer cell models and clinical patient response to inhibitors. Methods: An optimal two-layer decision system model is developed to identify the cancer cells that most closely resemble an individual tumor for optimum therapeutic interventions in precision cancer medicine. Accordingly, an optimal grid parameters selection is designed to seek the highest accordance for treatment selection to the patient\u2019s preference for drug response and in vitro cancer cell drug screening. The optimal two-layer decision system model overcomes the challenge of heterology data comparison between the tumor and the cancer cells, as well as between the continual variation of drug responses in vitro and the discrete ones in clinical practice. We simulated the model accuracy using 681 cancer cells\u2019 mRNA and associated 481 drug screenings and validated our results on 315 breast cancer patients drug selection across seven drugs (docetaxel, doxorubicin, fluorouracil, paclitaxel, tamoxifen, cyclophosphamide, lapitinib). Results: Comparing with the real response of a drug in clinical patients, the novel model obtained an overall average accordance over 90.8% across the seven drugs. At the same time, the optimal cancer cells and the associated optimal therapeutic efficacy of cancer drugs are recommended. The novel optimal two-layer decision system model was used on 1097 patients with breast cancer in guiding precision medicine for a recommendation of their optimal cancer cells (30 cancer cells) and associated efficacy of certain cancer drugs. Our model can detect the most similar cancer cells for each individual patient. Conclusion: A successful clinical translation model (optimal two-layer decision system model) was developed to bridge in-vitro basic science to clinical practice in a therapeutic intervention application for the first time. The novel tool kills two birds with one stone. It can help basic science to seek optimal cancer cell models for an individual tumor, while prioritizing clinical drugs\u2019 recommendations in practice. Tool associated platform website: We extended the breast cancer research to 32 more types of cancers across 45 therapy predictions.<\/jats:p>","DOI":"10.3390\/genes11030263","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T07:35:30Z","timestamp":1583134530000},"page":"263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine"],"prefix":"10.3390","volume":"11","author":[{"given":"Lijun","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Majumdar","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Stover","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaofeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-0571","authenticated-orcid":false,"given":"Yaoqin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Occupational and Environmental Health, School of Public Health, XinJiang Medical University, Urumqi 830011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jamia\/ocw004","article-title":"A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients","volume":"23","author":"Cheng","year":"2016","journal-title":"J. Am. Med Inform. Assoc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9404","DOI":"10.18632\/oncotarget.7012","article-title":"Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/pgs.14.170","article-title":"In vitro hman cell line models to predict clinical response to anticancer drugs","volume":"16","author":"Niu","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_4","first-page":"995","article-title":"An integrated approach to anti-cancer drug sensitivity prediction. IEEE\/ACM Trans","volume":"11","author":"Berlow","year":"2014","journal-title":"Comput. Biol. Bioinform."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1093\/bioinformatics\/bty452","article-title":"Predicting Cancer Drug Response using a Recommender System","volume":"34","author":"Suphavilai","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nbt.2877","article-title":"A community effort to assess and improve drug sensitivity prediction algorithms","volume":"32","author":"Costello","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1073\/pnas.1018854108","article-title":"Subtype and pathway specific responses to anticancer compounds in breast cancer","volume":"109","author":"Heiser","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013Mutant Advanced Melanoma Treated with Vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia","volume":"113","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00280-012-1886-y","article-title":"Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: Evidence from retrospective studies","volume":"69","author":"Wang","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_11","first-page":"101","article-title":"Implementation of biomarker-driven cancer therapy: Existing tools and remaining gaps","volume":"17","author":"Bailey","year":"2014","journal-title":"Discov. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.3748\/wjg.v23.i28.5045","article-title":"Precision medicine: In need of guidance and surveillance","volume":"23","author":"Lin","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Fr\u00f6hlich, H., Balling, R., Beerenwinkel, N., Kohlbacher, O., Kumar, S., Lengauer, T., Jones, V., Bodycombe, N.E., Soule, C.K., and Gould, C. (2018). From hype to reality: Data science enabling personalized medicine. BMC Med., 16.","DOI":"10.1186\/s12916-018-1122-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/2159-8290.CD-15-0945","article-title":"Large-Scale Drug Screens Support Precision Medicine","volume":"5","author":"Gray","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","article-title":"Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset","volume":"5","author":"Rees","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jiang, G., Zhang, S., Yazdanparast, A., Li, M., Pawar, A.V., Liu, Y., Inavolu, S.M., and Cheng, L. (2016). Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genom., 17.","DOI":"10.1186\/s12864-016-2911-z"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Delord","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/psp4.12167","article-title":"IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer","volume":"6","author":"Inavolu","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s40484-017-0126-1","article-title":"PMTDS: A computational method based on genetic interaction networks for Precision Medicine Target-Drug Selection in cancer","volume":"5","author":"Vasudevaraja","year":"2017","journal-title":"Quant. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Rees","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","article-title":"An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules","volume":"154","author":"Basu","year":"2013","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/gb-2014-15-3-r47","article-title":"Clinical drug response can be predicted using baseline gene expression levels and in vitrodrug sensitivity in cell lines","volume":"15","author":"Geeleher","year":"2014","journal-title":"Genome Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/bioinformatics\/btw344","article-title":"Evaluating the molecule-based prediction of clinical drug responses in cancer","volume":"32","author":"Ding","year":"2016","journal-title":"Bioinformatics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1038\/ncomms7169","article-title":"Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity","volume":"6","author":"Majumder","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1046-2023(03)00155-5","article-title":"Normalization of cDNA microarray data","volume":"31","author":"Smyth","year":"2003","journal-title":"Methods"},{"key":"ref_28","unstructured":"Glasnapp, D.R., and Poggio, J.P. (1985). Essentials of Statistical Analysis for the Behavioral Sciences, CE Merrill Pub. Co."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: A next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/3\/263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:02:32Z","timestamp":1760173352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/3\/263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["genes11030263"],"URL":"https:\/\/doi.org\/10.3390\/genes11030263","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]}}}